Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: Results from the international metastatic renal cell carcinoma database consortium

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages 311-315

  Vickers, Michael M ^a   Al Harbi, Hulayel ^a   Choueiri, Toni K ^b   Kollmannsberger, Christian ^c   North, Scott ^d   Mackenzie, Mary ^e   Knox, Jennifer J ^f   Rini, Brian I ^g   Heng, Daniel Y C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e London Health Centre   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Brain metastases; Mammalian targets of rapamycin; Renal cell carcinoma; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER CENTER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NEUROLOGIC DISEASE; NEUROSURGERY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY;

BRAIN METASTASES; MAMMALIAN TARGETS OF RAPAMYCIN; RENAL CELL CARCINOMA; TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; SIROLIMUS; SURVIVAL; TREATMENT OUTCOME;

EID: 84883464608     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.012     Document Type: Article

References (19)

1. R.J. Motzer, N.H. Bander, D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
2. M. Bianchi, M. Sun, C. Jeldres Distribution of metastatic sites in renal cell carcinoma: a population-based analysis Ann Oncol 23 2012 973 980
3. B. Shuch, J.C. La Rochelle, T. Klatte Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival Cancer 113 2008 1641 1648
4. J. Brugarolas Renal-cell carcinoma: molecular pathways and therapies N Engl J Med 356 2007 185 187
5. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
6. B. Escudier, T. Eisen, W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
7. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
8. B. Escudier, J. Bellmunt, S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
9. B.I. Rini, S. Halabi, J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
10. G. Hudes, M. Carducci, P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
11. R.J. Motzer, B. Escudier, S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
12. M.E. Gore, S. Hariharan, C. Porta Sunitinib in metastatic renal cell carcinoma patients with brain metastases Cancer 117 2011 501 509
13. C. Massard, J. Zonierek, M. Gross-Goupil Incidence of brain metastases in renal cell carcinoma treated with sorafenib Ann Oncol 21 2010 1027 1031
14. P.W. Sperduto, S.T. Chao, P.K. Sneed Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients Int J Radiat Oncol Biol Phys 77 2010 655 661
15. P. Breedveld, D. Pluim, G. Cipriani The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res 65 2005 2577 2582
16. S. Hu, Z. Chen, R. Franke Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters Clin Cancer Res 15 2009 6062 6069
17. D.Y. Heng, W. Xie, M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
18. S. Culine, M. Bekradda, A. Kramar Prognostic factors for survival in patients with brain metastases from renal cell carcinoma Cancer 83 1998 2548 2553
19. Kidney cancer National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v. National Comprehensive Cancer Network [Web site] www.nccn.org Accessed: May 1, 2013